Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Dec 10:3:e04037.
doi: 10.7554/eLife.04037.

Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors

Affiliations
Comment

Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors

Edward Greenfield et al. Elife. .

Abstract

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered Report describes the proposed replication plan of key experiments from "Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors" by Wilson and colleagues, published in Nature in 2012 (Wilson et al., 2012). The experiments that will be replicated are those reported in Figure 2B and C. In these experiments, Wilson and colleagues show that sensitivity to receptor tyrosine kinase (RTK) inhibitors can be bypassed by various ligands through reactivation of downstream signaling pathways (Figure 2A; Wilson et al., 2012), and that blocking the receptors for these bypassing ligands abrogates their ability to block sensitivity to the original RTK inhibitor (Figure 2C; Wilson et al., 2012). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.

Keywords: Reproducibility Project: Cancer Biology; biochemistry; human; methodology; receptor tyrosine kinase inhibitors; signaling pathway reactivation.

PubMed Disclaimer

Conflict of interest statement

EG: The Monoclonal Antibody Core Facility is a Science Exchange associated laboratory.

RP:CB: EI, FT and JL are employed and holds shares in Science Exchange Inc.

The other authors declare that no competing interests exist.

Comment on

Similar articles

Cited by

References

    1. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nature Reviews. Clinical Oncology. 2014;11:473–481. doi: 10.1038/nrclinonc.2014.104. - DOI - PubMed
    1. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Research. 2009;69:5292–5293. doi: 10.1158/0008-5472.CAN-09-1528. - DOI - PubMed
    1. Chen YF, Fu LW. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B. 2011;1:197–207. doi: 10.1016/j.apsb.2011.10.007. - DOI - PMC - PubMed
    1. Faul F, Erdfelder E, Lang AG, Buchner A. G* Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research methods. 2007;39:175–191. doi: 10.3758/BF03193146. - DOI - PubMed
    1. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung Cancer. Journal of Clinical Oncology. 2013;31:3987–3996. doi: 10.1200/JCO.2012.45.2029. - DOI - PMC - PubMed

MeSH terms

Grants and funding

The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funder had no role in study design or the decision to submit the work for publication.